CCL21 Cancer Immunotherapy

Cancers

Yuan Lin¹  Sherven Sharma² 

[1] Department of Head and Neck Surgery, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA;Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA

关键词: CCL21;    cancer immunotherapy;    dendritic cell;    polymer;    T cell;   

DOI  :  10.3390/cancers6021098

来源: mdpi

【 摘 要 】

Cancer, a major health problem, affects 12 million people worldwide every year. With surgery and chemo-radiation the long term survival rate for the majority of cancer patients is dismal. Thus novel treatments are urgently needed. Immunotherapy, the harnessing of the immune system to destroy cancer cells is an attractive option with potential for long term anti-tumor benefit. Cytokines are biological response modifiers that stimulate anti-tumor immune responses. In this review, we discuss the anti-tumor efficacy of the chemotactic cytokine CCL21 and its pre-clinical and clinical application in cancer.

【 授权许可】

CC BY   
© 2014 by the authors; licensee MDPI, Basel, Switzerland.